Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 28;15(1):141–157. doi: 10.1111/cts.13149

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 F. Hoffmann‐La Roche/Genentech, Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Meta‐analysis comparing ADA+/NAb+ experimental‐arm patients to adjusted control‐arm patients. Forest plots for (a) OS and (b) PFS are shown only for studies with an overall treatment effect. 1L, first line; 2L+, second line and beyond; ADA, anti‐drug antibody; CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; mUC, metastatic urothelial carcinoma; NAb, neutralizing (anti‐drug) antibody; NSCLC, non‐small cell lung cancer; NSq, nonsquamous; OS, overall survival; PFS, progression‐free survival; RCC, renal cell carcinoma; SCLC, small cell lung cancer; Sq, squamous